CN117164590A - Fused pyrimidine derivative and application thereof - Google Patents
Fused pyrimidine derivative and application thereof Download PDFInfo
- Publication number
- CN117164590A CN117164590A CN202210578200.XA CN202210578200A CN117164590A CN 117164590 A CN117164590 A CN 117164590A CN 202210578200 A CN202210578200 A CN 202210578200A CN 117164590 A CN117164590 A CN 117164590A
- Authority
- CN
- China
- Prior art keywords
- pyrimidine
- substituted
- dimethyl
- methylmorpholin
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003230 pyrimidines Chemical class 0.000 title claims description 16
- -1 pyrimidine compound Chemical class 0.000 claims abstract description 139
- 150000001875 compounds Chemical class 0.000 claims abstract description 68
- 239000000651 prodrug Substances 0.000 claims abstract description 29
- 229940002612 prodrug Drugs 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 239000012453 solvate Substances 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 5
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 3
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 70
- 125000003545 alkoxy group Chemical group 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 36
- 125000005843 halogen group Chemical group 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 16
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims description 15
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 14
- 125000003277 amino group Chemical group 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 125000004043 oxo group Chemical group O=* 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000005257 alkyl acyl group Chemical group 0.000 claims description 9
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 9
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 9
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000002950 monocyclic group Chemical group 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 125000003367 polycyclic group Chemical group 0.000 claims description 3
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 201000009036 biliary tract cancer Diseases 0.000 claims description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 238000002360 preparation method Methods 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 4
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 description 51
- 238000006243 chemical reaction Methods 0.000 description 48
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 44
- 230000015572 biosynthetic process Effects 0.000 description 27
- 238000003786 synthesis reaction Methods 0.000 description 27
- 239000000243 solution Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- 108091000080 Phosphotransferase Proteins 0.000 description 10
- 102000020233 phosphotransferase Human genes 0.000 description 10
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 238000001308 synthesis method Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- YREPHXXOTHNLEV-UHFFFAOYSA-N ethyl 2-amino-2-methylpropanoate;hydrochloride Chemical compound Cl.CCOC(=O)C(C)(C)N YREPHXXOTHNLEV-UHFFFAOYSA-N 0.000 description 8
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000012295 chemical reaction liquid Substances 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- JZCWLJDSIRUGIN-UHFFFAOYSA-N 3-[3-[4-(methylaminomethyl)phenyl]-5-isoxazolyl]-5-(4-propan-2-ylsulfonylphenyl)-2-pyrazinamine Chemical compound C1=CC(CNC)=CC=C1C1=NOC(C=2C(=NC=C(N=2)C=2C=CC(=CC=2)S(=O)(=O)C(C)C)N)=C1 JZCWLJDSIRUGIN-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229940067621 aminobutyrate Drugs 0.000 description 4
- 125000006278 bromobenzyl group Chemical group 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 4
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- OHUHVTCQTUDPIJ-JYCIKRDWSA-N ceralasertib Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 OHUHVTCQTUDPIJ-JYCIKRDWSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- SFWWGMKXCYLZEG-RXMQYKEDSA-N (3r)-3-methylmorpholine Chemical compound C[C@@H]1COCCN1 SFWWGMKXCYLZEG-RXMQYKEDSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QDCIXBBEUHMLDN-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-indole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC2=C1C=CN2 QDCIXBBEUHMLDN-UHFFFAOYSA-N 0.000 description 2
- 102000000872 ATM Human genes 0.000 description 2
- 229940125774 BAY 1895344 Drugs 0.000 description 2
- YBXRSCXGRPSTMW-CYBMUJFWSA-N C[C@@H]1COCCN1C1=CC(C2=CC=NN2C)=C2C=CN=C(C3=CC=NN3)C2=N1 Chemical compound C[C@@H]1COCCN1C1=CC(C2=CC=NN2C)=C2C=CN=C(C3=CC=NN3)C2=N1 YBXRSCXGRPSTMW-CYBMUJFWSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000006264 debenzylation reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- IOLQWGVDEFWYNP-UHFFFAOYSA-N ethyl 2-bromo-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)Br IOLQWGVDEFWYNP-UHFFFAOYSA-N 0.000 description 2
- FQTIYMRSUOADDK-UHFFFAOYSA-N ethyl 3-bromopropanoate Chemical compound CCOC(=O)CCBr FQTIYMRSUOADDK-UHFFFAOYSA-N 0.000 description 2
- CXVQSUBJMYZELD-UHFFFAOYSA-N ethyl 4-aminobutanoate;hydrochloride Chemical compound [Cl-].CCOC(=O)CCC[NH3+] CXVQSUBJMYZELD-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 125000000493 isoindolonyl group Chemical group C1(N=C(C2=CC=CC=C12)*)=O 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000028617 response to DNA damage stimulus Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000005783 single-strand break Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000003797 solvolysis reaction Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 125000002769 thiazolinyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- BHKRMQZNFPIGNQ-UHFFFAOYSA-N 3-methylsulfonylbenzoyl chloride Chemical compound CS(=O)(=O)C1=CC=CC(C(Cl)=O)=C1 BHKRMQZNFPIGNQ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PATULTXBGPQXAI-UHFFFAOYSA-N 4-sulfonylcyclohexa-1,5-diene-1-carbonyl chloride Chemical compound ClC(=O)C1=CCC(=S(=O)=O)C=C1 PATULTXBGPQXAI-UHFFFAOYSA-N 0.000 description 1
- YAWHBAVAZKATQR-UHFFFAOYSA-N 7-benzyl-2,4-dichloro-8,8-dimethyl-5,6-dihydropyrido[3,4-d]pyrimidine Chemical compound C(C1=CC=CC=C1)N1C(C=2N=C(N=C(C=2CC1)Cl)Cl)(C)C YAWHBAVAZKATQR-UHFFFAOYSA-N 0.000 description 1
- PJYJUQOWDLAXCI-UHFFFAOYSA-N 7-benzyl-8,8-dimethyl-5,6-dihydro-1H-pyrido[3,4-d]pyrimidine-2,4-dione Chemical compound C=12NC(=O)NC(=O)C=1CCN(C2(C)C)CC1=CC=CC=C1 PJYJUQOWDLAXCI-UHFFFAOYSA-N 0.000 description 1
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 101000785063 Homo sapiens Serine-protein kinase ATM Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101710150974 Regulator of chromosome condensation Proteins 0.000 description 1
- 102100039977 Regulator of chromosome condensation Human genes 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229950009676 berzosertib Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940121422 ceralasertib Drugs 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- FXORZKOZOQWVMQ-UHFFFAOYSA-L dichloropalladium;triphenylphosphane Chemical compound Cl[Pd]Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 FXORZKOZOQWVMQ-UHFFFAOYSA-L 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a novel condensed pyrimidine compound shown in a general formula I or stereoisomer, pharmaceutically acceptable salt, solvate or prodrug thereof, and a preparation method and application thereof 1 、R 2 A, Y, L, n have the meanings given in the description. The invention also relates to application of the compounds and pharmaceutically acceptable salts, solvates or prodrugs thereof in preparing medicaments for treating diseases caused by abnormal high expression of ATR, in particular to preparation of medicaments for treating the diseases caused by abnormal high expression of ATRThe use in medicaments for the treatment and/or prevention of hyperproliferative diseases, including but not limited to gastric cancer, liver cancer, colorectal cancer, ovarian cancer, pancreatic cancer and the like.
Description
Technical Field
The invention relates to the field of pharmaceutical chemistry, in particular to a fused pyrimidine derivative and application thereof.
Background
Ataxia telangiectasia mutated and Rad3 related kinase (ATR) is a serine/threonine protein kinase that forms part of the DNA Damage Response (DDR) with ATM and DNA-PK, coordinating the response of cells to DNA damage, stress and cell cycle disturbances. ATR is critical for viability of replicating cells that respond to accumulation of Single Strand Breaks (SSBs) in DNA (e.g., stagnant replication forks) and massive DNA damage (e.g., damage from chemotherapeutics and uv radiation). The sensitivity of tumor cells to chemotherapeutic agents has been shown to be caused by genetic modulation of ATR activity.
ATR kinase is responsible for initiating the response and repair of cells to genomic instability, and once DNA damage and replication cross stress are felt, they are rapidly activated, directly phosphorylating more than 1000 important substrates (including the oncogene p53 encoded protein, cell cycle regulatory protein, etc.) within the cell, globally regulating the stability of the genome. Cancer cells typically have high levels of oncogene-induced replicative stress, which are more dependent on ATR kinase. ATR kinase inhibitors can interfere with DNA repair, promote cancer cell DNA to be errant and not repaired, and ultimately promote tumor cell apoptosis. Studies have shown that upregulation of ATR expression, such as liver, stomach, ovarian, pancreatic, gastric, etc., is observed in a variety of tumor tissues, and that patients with high levels of ATR are often accompanied by low survival rates. ATR is seen as an important tumor therapeutic target, and ATR inhibitors are also important antitumor drugs.
Compounds currently in preclinical and clinical research stages include CeraLasertib (AZD-6738), berzosertib (VX-970, M6620), BAY1895344, M4344, etc., wherein AZD-6738 and VX-970 are currently in clinical stage II, and BAY-1895344 and M4344 are in clinical stage I. Although some ATR inhibitors have been reported, no ATR inhibitors have yet been marketed, and there remains a need in the art for new ATR inhibitors, particularly those having high activity and other superior properties.
The invention comprises the following steps:
the invention aims to provide a novel fused pyrimidine derivative and application thereof.
In order to achieve the above purpose, the invention adopts the technical scheme that:
a fused pyrimidine derivative is a compound shown in a general formula I and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a prodrug thereof,
wherein,
R 1 and R is 2 Together with the nitrogen atom to which they are attached form a 4-10 membered heterocyclic group containing at least 1-4 heteroatoms, said heterocyclic group optionally being substituted with 1-3R's, which may be the same or different 3 Optionally substituted with 1-2 oxo groups;
R 3 is H, cyano, halogen, (C) 1 -C 6 ) Alkyl, halo (C) 1 -C 6 ) Alkyl, (C) 1 -C 6 ) Alkoxy, (halo) C 1 -C 6 ) Alkoxy, carboxyl, (C1-C6) alkoxycarbonyl, carbamoyl which is unsubstituted or substituted by 1-2 (C1-C6) alkyl;
a is unsubstituted or substituted by 1 to 3 identical or different R 4 Substituted 4-10 membered heterocyclyl, (C6-C10) aryl, 5-10 membered heteroaryl;
n is 1, 2 or 3;
y is-C (O) -, -S (O) 2 -、-S(O)-、-C(S)-、-CH 2 -、-C(O)CH 2 -、-CH 2 C(O)-;
L is unsubstituted or substituted by 1 to 3 identical or different R 7 Substituted (C) 1 -C 6 ) Alkyl, (C) 1 -C 6 ) Alkoxy, (C) 2 -C 6 ) Alkenyl group (C) 3 -C 6 ) Cycloalkyl, (C) 6 -C 10 ) Aryl, 5-10 membered heteroaryl, -NR 5 R 6 ;
R 5 、R 6 The same or different are each independently selected from hydrogen, (C) 1 -C 6 ) Alkyl, (C) 3 -C 6 ) Cycloalkyl, 4-10 membered heterocyclyl, (C) 6 -C 10 ) Aryl, 5-10 membered heteroaryl;
or R is 5 And R is 6 Together with the nitrogen atom to which they are attached, form a 4-10 membered heterocyclic group containing at least 1-4 heteroatoms, said heterocyclic group optionally being substituted with 1-2 oxo groups;
R 4 ,R 7 is halogen, hydroxy, nitro, cyano, carboxyl, (C) 1 -C 6 ) Alkyl, (C) 1 -C 6 ) Alkoxy, halo (C) 1 -C 6 ) Alkyl, halo (C) 1 -C 6 ) Alkoxy, (C) 1 -C 6 ) Alkyl acyl group (C) 1 -C 6 ) Alkoxycarbonyl, (C) 1 -C 6 ) Alkylamido group (C) 1 -C 6 ) Alkylsulfinyl, (C) 1 -C 6 ) Alkylsulfonyl, (C) 1 -C 3 ) Alkylene dioxy, unsubstituted or substituted by 1 to 2 (C) 1 -C 6 ) Amino substituted by alkyl, unsubstituted or substituted by 1-2 (C 1 -C 6 ) Alkyl groupSubstituted carbamoyl;
the aryl is phenyl or naphthyl; heteroaryl is a monocyclic or polycyclic unsaturated cyclic system containing one or more heteroatoms, wherein the cyclic system is aromatic and is imidazolyl, pyrazolyl, pyridinyl, indolyl, azaindolyl, benzimidazolyl, benzopyrazolyl, indolonyl, isoindolonyl, pyrazolyl, furanyl, thienyl, pyrrolyl, thiazolyl, benzothiazolyl, oxazolyl, isoxazolyl, quinolinyl, isoquinolinyl, benzoxazolyl; heterocyclyl is a saturated or partially saturated monocyclic, polycyclic, bridged or spiro ring system containing one or more heteroatoms, wherein the ring system is pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, indolinyl or thiazolinyl.
Preferably, the derivative is a compound of formula I and stereoisomers, pharmaceutically acceptable salts, solvates or prodrugs thereof,
wherein,
R 1 and R is 2 Together with the nitrogen atom to which they are attached form a 4-10 membered heterocyclic group containing at least 1-3 heteroatoms, said heterocyclic group optionally being substituted with 1-2R's, which may be the same or different 3 Substituted or substituted with 1-2 oxo groups;
R 3 is H, cyano, halogen, (C) 1 -C 4 ) Alkyl, (C) 1 -C 4 ) Alkoxy, halo (C) 1 -C 4 ) Alkyl, halo (C) 1 -C 4 ) Alkoxy, carboxyl, (C) 1 -C 4 ) Alkoxycarbonyl, unsubstituted or substituted by 1 to 2 (C) 1 -C 4 ) Amino substituted by alkyl, unsubstituted or substituted by 1-2 (C 1 -C 4 ) An alkyl-substituted carbamoyl group;
a is unsubstituted or substituted by 1-2 identical or different R 4 Substituted 4-10 membered heterocyclyl, (C) 6 -C 10 ) Aryl, 5-10 membered heteroaryl;
n is 1 or 2;
y is-C (O) -, -S (O) 2 -、-C(O)CH 2 -、-CH 2 C(O)-;
L is unsubstituted or substituted 1-3 identical or different R' s 7 Substituted (C) 1 -C 4 ) Alkyl, (C) 1 -C 4 ) Alkoxy, (C) 2 -C 4 ) Alkenyl group (C) 3 -C 6 ) Cycloalkyl, (C) 6 -C 10 ) Aryl, 5-10 membered heteroaryl, -NR 5 R 6 ;
R 5 、R 6 The same or different are each independently selected from hydrogen, (C) 1 -C 4 ) Alkyl, (C) 3 -C 4 ) Cycloalkyl, 4-10 membered heterocyclyl, (C) 6 -C 10 ) Aryl, 5-6 membered heteroaryl;
or R is 5 And R is 6 Together with the nitrogen atom to which they are attached, form a 4-10 membered heterocyclic group containing at least 1-4 heteroatoms, said heterocyclic group optionally being substituted with 1-2 oxo groups;
R 4 ,R 7 Is halogen, hydroxy, nitro, cyano, carboxyl, (C) 1 -C 4 ) Alkyl, (C) 1 -C 4 ) Alkoxy, halo (C) 1 -C 4 ) Alkyl, halo (C) 1 -C 4 ) Alkoxy, (C) 1 -C 4 ) Alkyl acyl group (C) 1 -C 4 ) Alkoxycarbonyl, (C) 1 -C 4 ) Alkylamido group (C) 1 -C 4 ) Alkylsulfinyl, (C) 1 -C 4 ) Alkylsulfonyl, (C) 1 -C 3 ) Alkylene dioxy, unsubstituted or substituted by 1 to 2 (C) 1 -C 4 ) Amino substituted by alkyl, unsubstituted or substituted by 1-2 (C 1 -C 4 ) An alkyl-substituted carbamoyl group.
Still more preferably, the derivative is a compound represented by the general formula I and stereoisomers, pharmaceutically acceptable salts, solvates or prodrugs thereof,
wherein,
R 1 and R is 2 Together with the nitrogen atom to which they are attached form a 4-10 membered heterocyclic group containing at least 1-2 heteroatoms, said heterocyclic group optionally being substituted with 1-2R's, which may be the same or different 3 Substituted or substituted with 1-2 oxo groups;
R 3 is H, cyano, halogen, (C) 1 -C 4 ) Alkyl, (C) 1 -C 4 ) Alkoxy, halo (C) 1 -C 4 ) Alkyl, halo (C) 1 -C 4 ) Alkoxy, carboxyl, (C) 1 -C 4 ) Alkoxycarbonyl, unsubstituted or substituted by 1 to 2 (C) 1 -C 4 ) Amino substituted by alkyl, unsubstituted or substituted by 1-2 (C 1 -C 4 ) An alkyl-substituted carbamoyl group;
a is unsubstituted or substituted by 1-2 identical or different R 4 Substituted 4-10 membered heterocyclyl, (C) 6 -C 10 ) Aryl, 5-10 membered heteroaryl;
n is 1 or 2;
y is-C (O) -, -S (O) 2 -、-C(O)CH 2 -、-CH 2 C(O)-;
L is unsubstituted or substituted by 1 to 3 identical or different R 7 Substituted (C) 1 -C 4 ) Alkyl, (C) 3 -C 6 ) Cycloalkyl, phenyl, 5-10 membered heteroaryl, -NR 5 R 6 ;
R 4 ,R 7 Is halogen, hydroxy, nitro, cyano, carboxyl, (C) 1 -C 4 ) Alkyl, (C) 1 -C 4 ) Alkoxy, halo (C) 1 -C 4 ) Alkyl, halo (C) 1 -C 4 ) Alkoxy, (C) 1 -C 4 ) Alkyl acyl group (C) 1 -C 4 ) Alkoxycarbonyl, (C) 1 -C 4 ) Alkylamido group (C) 1 -C 4 ) Alkylsulfinyl, (C) 1 -C 4 ) Alkylsulfonyl, (C) 1 -C 3 ) Alkylene dioxy, unsubstituted or substituted by 1 to 2 (C) 1 -C 4 ) Amino substituted by alkyl, unsubstituted or substituted by 1-2 (C 1 -C 4 ) An alkyl-substituted carbamoyl group.
Further preferably, the derivative is a compound shown in a general formula I and stereoisomers, pharmaceutically acceptable salts, solvates or prodrugs thereof,
wherein,
R 1 and R is 2 Together with the nitrogen atom to which they are attached form a 4-10 membered heterocyclic ring containing at least 1-2 heteroatomsA radical, said heterocyclyl optionally being substituted with 1 to 2 identical or different R' s 3 Substituted or substituted with 1-2 oxo groups;
R 3 is H, cyano, halogen, (C) 1 -C 4 ) Alkyl, (C) 1 -C 4 ) Alkoxy, halo (C) 1 -C 4 ) Alkyl, halo (C) 1 -C 4 ) Alkoxy, carboxyl, (C) 1 -C 4 ) Alkoxycarbonyl, unsubstituted or substituted by 1 to 2 (C) 1 -C 4 ) Amino substituted by alkyl, unsubstituted or substituted by 1-2 (C 1 -C 4 ) An alkyl-substituted carbamoyl group;
a is unsubstituted or substituted by 1-2 identical or different R 4 Substituted 4-10 membered heterocyclyl, (C) 6 -C 10 ) Aryl, 5-10 membered heteroaryl;
n is 1 or 2;
y is-C (O) -, -S (O) 2 -、-C(O)CH 2 -、-CH 2 C(O)-;
L is (C) 1 -C 4 ) Alkyl, (C) 3 -C 6 ) Cycloalkyl, phenyl, 5-10 membered heteroaryl, and the aforementioned L may also optionally be substituted with 1-3R's, which may be the same or different 7 Substitution;
R 4 ,R 7 is halogen, hydroxy, nitro, cyano, carboxyl, (C) 1 -C 4 ) Alkyl, (C) 1 -C 4 ) Alkoxy, halo (C) 1 -C 4 ) Alkyl, halo (C) 1 -C 4 ) Alkoxy, (C) 1 -C 4 ) Alkyl acyl group (C) 1 -C 4 ) Alkoxycarbonyl, (C) 1 -C 4 ) Alkylamido group (C) 1 -C 4 ) Alkylsulfinyl, (C) 1 -C 4 ) Alkylsulfonyl, (C) 1 -C 3 ) Alkylene dioxy, unsubstituted or substituted by 1 to 2 (C) 1 -C 4 ) Amino substituted by alkyl, unsubstituted or substituted by 1-2 (C 1 -C 4 ) An alkyl-substituted carbamoyl group.
More preferably, the derivative is a compound shown in a general formula I and stereoisomers, pharmaceutically acceptable salts, solvates or prodrugs thereof,
wherein,
R 1 and R is 2 Together with the nitrogen atom to which they are attached, form the structure:
a is unsubstituted or substituted by 1-2 identical or different R 4 Substituted 4-10 membered heterocyclyl, (C) 6 -C 10 ) Aryl, 5-10 membered heteroaryl;
n is 1 or 2;
y is-C (O) -;
l is (C) 1 -C 4 ) Alkyl, (C) 3 -C 6 ) Cycloalkyl, phenyl, 5-10 membered heteroaryl, and the aforementioned L may also optionally be substituted with 1-3R's, which may be the same or different 7 Substitution;
R 4 ,R 7 is halogen, hydroxy, nitro, cyano, carboxyl, (C) 1 -C 4 ) Alkyl, (C) 1 -C 4 ) Alkoxy, halo (C) 1 -C 4 ) Alkyl, halo (C) 1 -C 4 ) Alkoxy, (C) 1 -C 4 ) Alkyl acyl group (C) 1 -C 4 ) Alkoxycarbonyl, (C) 1 -C 4 ) Alkylamido group (C) 1 -C 4 ) Alkylsulfinyl, (C) 1 -C 4 ) Alkylsulfonyl, (C) 1 -C 3 ) Alkylene dioxy, unsubstituted or substituted by 1 to 2 (C) 1 -C 4 ) Amino substituted by alkyl, unsubstituted or substituted by 1-2 (C 1 -C 4 ) An alkyl-substituted carbamoyl group.
Still more preferably, the compounds of formula I and stereoisomers, pharmaceutically acceptable salts, solvates or prodrugs thereof,
wherein,
R 1 and R is 2 Together with the nitrogen atom to which they are attached, form the structure:
a is And A is optionally substituted with 1 to 3R's, which may be the same or different 4 And (3) substitution.
n is 1 or 2;
y is-C (O) -;
l is (C) 1 -C 4 ) Alkyl, (C) 3 -C 6 ) Cycloalkyl, phenyl, 5-10 membered heteroaryl, and the aforementioned L may also optionally be substituted with 1-3R's, which may be the same or different 7 Substitution;
R 4 ,R 7 is halogen, hydroxy, nitro, cyano, carboxyl, (C) 1 -C 4 ) Alkyl, (C) 1 -C 4 ) Alkoxy, halo (C) 1 -C 4 ) Alkyl, halo (C) 1 -C 4 ) Alkoxy, (C) 1 -C 4 ) Alkyl acyl group (C) 1 -C 4 ) Alkoxycarbonyl, (C) 1 -C 4 ) Alkylamido group (C) 1 -C 4 ) Alkylsulfinyl, (C) 1 -C 4 ) Alkylsulfonyl, (C) 1 -C 3 ) Alkylene dioxy, unsubstituted or substituted by 1 to 2 (C) 1 -C 4 ) Amino substituted by alkyl, unsubstituted or substituted by 1-2 (C 1 -C 4 ) An alkyl-substituted carbamoyl group.
Still further preferred are compounds of formula I and stereoisomers, pharmaceutically acceptable salts, solvates or prodrugs thereof,
wherein R is 1 And R is 2 Together with the nitrogen atom to which they are attached
n is 1 or 2;
y is-C (O) -;
l is unsubstituted or substituted by 1 to 3 identical or different R 7 Substituted (C) 1 -C 4 ) Alkyl, (C) 3 -C 6 ) Cycloalkyl, phenyl, thienyl, pyrrolyl, pyrazolyl, furyl, thiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, quinolinyl, isoquinolinyl, indolyl, benzothiazolyl, benzoxazolyl;
a is And A is optionally substituted with 1 to 3R's, which may be the same or different 4 And (3) substitution.
R 4 ,R 7 Is halogen, hydroxy, nitro, cyano, carboxyl, (C) 1 -C 4 ) Alkyl, (C) 1 -C 4 ) Alkoxy, halo (C) 1 -C 4 ) Alkyl, halo (C) 1 -C 4 ) Alkoxy, (C) 1 -C 4 ) Alkyl acyl group (C) 1 -C 4 ) Alkoxycarbonyl, (C) 1 -C 4 ) Alkylamido group (C) 1 -C 4 ) Alkylsulfinyl, (C) 1 -C 4 ) Alkylsulfonyl, (C) 1 -C 3 ) Alkylene dioxy, unsubstituted or substituted by 1 to 2 (C) 1 -C 4 ) Amino substituted by alkyl, unsubstituted or substituted by 1-2 (C 1 -C 4 ) An alkyl-substituted carbamoyl group.
The compounds of the general formula I and stereoisomers, pharmaceutically acceptable salts, solvates or prodrugs thereof are particularly preferred in the present invention, as obtained in examples 1-80 below.
Most particularly preferred in the context of the present invention are compounds of the general formula I and stereoisomers, pharmaceutically acceptable salts, solvates or prodrugs thereof,
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6-methanesulfonyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6-acetyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6-isopropyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6-cyclopropylcarbonyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6-propionyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6-methanesulfonyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6-cyclobutylformyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (3-methoxybenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (4-methoxybenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (3, 4-dimethoxybenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (1, 3-benzodioxol-5-yl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (2, 3-dihydrobenzo [ b ] [1,4] dioxin-6-carbonyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (4-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (3-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (4-difluoromethoxybenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (4-acetylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (3-acetylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7-methylsulfonyl 4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine;
(R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7-isopropylformyl-4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine;
(R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7-propionyl-4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine;
(R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7-benzoyl-4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine;
(R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7- (2-acryloyl) -4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine;
(R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7- (3-fluorobenzoyl) -4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine;
(R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7- (3, 4-dimethoxybenzoyl) -4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-7-azaindol-4-yl) -6-methanesulfonyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-7-azaindol-4-yl) -6-cyclopropylcarbonyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-7-azaindol-4-yl) -6-benzoyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-7-azaindol-4-yl) -6- (3-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (7-methyl-1H-indol-4-yl) -6- (3-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (7-methyl-1H-indol-4-yl) -6- (4-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (3 a,7 a-dihydro-1H-benzo [ d ] imidazol-1-yl) -6- (3-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (3 a,7 a-dihydro-1H-benzo [ d ] imidazol-1-yl) -6- (4-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indazol-4-yl) -6- (4-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-3-yl) -6- (4-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine.
Pharmaceutically acceptable salts of the compounds of formula I above are salts with acids selected from the group consisting of: hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, phosphoric acid, nitric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid, trifluoroacetic acid and aspartic acid.
The invention also includes prodrugs of the derivatives of the invention. Prodrugs of the derivatives of the invention are derivatives of formula (I) which may themselves have relatively weak or even no activity, but are converted to the corresponding biologically active form under physiological conditions (e.g. by metabolism, solvolysis or otherwise) after administration.
The "halogen" in the substituent means fluorine, chlorine or bromine; "alkyl" refers to a straight or branched chain alkyl group; "cycloalkyl" refers to a substituted or unsubstituted cycloalkyl; "alkoxy" refers to straight or branched chain alkoxy; "alkenyl" refers to straight or branched chain alkenyl groups; "alkynyl" refers to straight or branched chain alkynyl groups; "aryl" refers to phenyl or naphthyl that is unsubstituted or substituted; "heteroaryl" means a monocyclic or polycyclic ring system containing one or more heteroatoms selected from N, O, S, the ring system being aromatic, such as imidazolyl, pyridyl, indolyl, azaindolyl, benzimidazolyl, benzopyrazolyl, indolonyl, isoindolonyl, pyrazolyl, furanyl, thienyl, pyrrolyl, thiazolyl, benzothiazolyl, oxazolyl, isoxazolyl, quinolinyl, isoquinolinyl, benzoxazolyl, and the like; "saturated or partially saturated heterocyclyl" refers to a monocyclic, polycyclic, bridged or spiro ring system containing one or more heteroatoms selected from N, O, S, such as pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, pyrazolidinyl, indolinyl, imidazolidinyl, thiazolinyl, and the like.
A pharmaceutical composition comprising a compound of formula I, and stereoisomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, in admixture with a pharmaceutically acceptable carrier.
Use of a compound of formula I, or a stereoisomer, pharmaceutically acceptable salt, solvate or prodrug thereof, or a composition comprising a compound of formula I, or a stereoisomer, pharmaceutically acceptable salt, solvate or prodrug thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of ATR mediated diseases.
Such preparation is useful for the treatment and/or prevention of ATR mediated diseases including, but not limited to, osteosarcoma, glioblastoma, lung cancer, head and neck cancer, pancreatic cancer, gastric cancer, and brain cancer, non-small cell lung cancer, pancreatic cancer, biliary tract cancer, bladder cancer, colorectal cancer, breast cancer, ovarian cancer, multiple myeloma, skin cancer, melanoma, leukemia, or renal cancer.
The invention also includes prodrugs of the derivatives of the invention. Prodrugs of the derivatives of the invention are derivatives of formula (I) which may themselves have relatively weak or even no activity, but are converted to the corresponding biologically active form under physiological conditions (e.g. by metabolism, solvolysis or otherwise) after administration.
The invention also includes pharmaceutical compositions comprising as active ingredient a compound of formula I and pharmaceutically acceptable salts and/or solvates thereof, together with a pharmaceutically acceptable carrier; the compounds of the invention may also be used in combination with other active ingredients, provided that they do not produce other adverse effects, such as allergic reactions.
The carriers used in the pharmaceutical compositions of the present invention are of the usual types available in the pharmaceutical arts, including binders, lubricants, disintegrants, cosolvents, diluents, stabilizers, suspending agents, pigment-free, flavoring agents and the like, which are available for oral formulations; a pH regulator, an osmotic pressure regulator, a solubilizer, a stabilizer, etc. for injectable preparations; matrices, diluents, lubricants, preservatives, and the like, which may be used in topical formulations. Pharmaceutical formulations may be administered orally, parenterally (e.g., intravenously, subcutaneously, intraperitoneally, etc.), or topically (e.g., ocular, nasal, sublingual, dermal, etc.), and if some drugs are unstable under gastric conditions, they may be formulated as enteric coated tablets.
The precise amount of the compounds of the present invention to treat cancer, particularly diseases caused by ATR abnormalities, will vary from subject to subject, depending on the type of subject, the age and general condition, the severity of the disease being treated, the particular compound used, and the mode of administration, e.g., route and frequency of administration, etc. One of ordinary skill in the art can determine the appropriate effective amount using only routine experimentation.
The amount of the compound administered may be from about 0.1 to 160mg/kg body weight per day, preferably 1 to 60mg/kg body weight per day. It will be appreciated that the dosage may vary depending on the patient's needs, the disease caused by the abnormality of ATR being treated and the particular compound being used. Moreover, it will be appreciated that the initial dose administered may be increased beyond an upper limit in order to rapidly reach the desired blood level, or the initial dose may be less than optimal, and the daily dose may be gradually increased during treatment, depending on the particular situation. If desired, the daily dose may also be divided into multiple doses, for example 2-4 times per day.
Mammal means a human or an animal.
The amount of active ingredient, i.e. the compound according to the invention, in the pharmaceutical composition and unit dosage forms thereof may vary depending on the particular application, the potency of the particular compound and the desired concentration. Generally, the content of active ingredient will be between 0.5% and 90% by total weight of the composition.
In combination therapy, the compound of the invention and the other compound may be administered simultaneously or separately, and in the case of simultaneous administration, the compound of the invention and the other compound may be combined in a single pharmaceutical composition or in separate compositions.
The examples and preparations provided below further illustrate and exemplify the compounds of the invention and methods of preparing the same. It should be understood that the scope of the following examples and preparations is not intended to limit the scope of the present invention in any way.
The following synthetic schemes describe the preparation of the derivatives of formula I of the present invention, all starting materials being prepared by the methods described in these synthetic schemes, by methods well known to those of ordinary skill in the art of organic chemistry, or are commercially available. All of the final compounds of the present invention are prepared by methods described in these synthetic routes or by methods analogous thereto, which are well known to those of ordinary skill in the art of organic chemistry. All variable factors applied in these synthetic routes are as defined below or as defined in the claims.
In the compounds of the general formula I according to the invention, in the first to fourth routes, the following compounds are exemplified, and the substituents R1, R2 and Y, L are as defined above.
In the first route, 2-amino isobutyric acid is used as a starting material, intermediate 1 is obtained through esterification, intermediate 2 is obtained through substitution reaction of intermediate 1 and 3-bromopropionic acid ethyl ester, intermediate 3 is obtained through nucleophilic substitution of intermediate 2 and bromobenzyl, intermediate 4 is obtained through Claisen ester condensation of intermediate 3 under the action of sodium ethoxide, intermediate 5 is obtained through cyclization of intermediate 4 and urea at high temperature, intermediate 6 is obtained through chlorination, intermediate 7 is obtained through nucleophilic substitution reaction of intermediate 6 and R1R2 substituted amine, intermediate 9 is obtained through Suzuki coupling and debenzylation of intermediate 7 and different substituted boric acid esters, and I-I is obtained through reaction of intermediate 9 and alkyl or aromatic halide, alkyl or aromatic acyl chloride, alkyl or aromatic sulfonyl chloride.
In the second route, 4-aminobutyric acid is taken as a starting material, intermediate 10 is obtained through esterification, intermediate 10 and ethyl 2-bromoisobutyrate are subjected to substitution reaction to obtain intermediate 11, then intermediate 12 is obtained through nucleophilic substitution reaction with bromobenzyl, intermediate 12 is condensed with Claisen ester under the action of sodium ethoxide to obtain intermediate 13, then intermediate 14 is obtained through cyclization with urea under the action of sodium methoxide, intermediate 15 is obtained through chlorination reaction of intermediate 14, and intermediate 15 and R 1 R 2 The substituted amine is subjected to nucleophilic substitution reaction to obtain an intermediate 16, the intermediate 16 and different substituted boric acid esters are subjected to Suzuki coupling to obtain an intermediate 17, the intermediate 17 is debenzylated under the action of palladium hydroxide/carbon to obtain an intermediate 18, and then the intermediate 18 is reacted with alkyl or aromatic halide, alkyl or aromatic chlorine, alkyl or aromatic sulfonyl chloride to obtain I-ii.
In the second route, intermediate 19 is taken as a raw material, and debenzylation is carried out under the action of chloroformate-1-chloroethyl to obtain intermediate 20, intermediate 20 reacts with different substituted aliphatic or aromatic acyl chlorides and different substituted aliphatic or aromatic sulfonyl chlorides to obtain intermediate 21, and intermediate 20 reacts with different substituted boric acid esters to obtain I-iii.
In the fourth route, 19 is used as a raw material, intermediate 22 is obtained through Suzuki coupling, intermediate 22 is debenzylated under the action of palladium hydroxide/carbon to obtain intermediate 23, and intermediate 23 reacts with different substituted active esters to obtain I-iv.
The compound containing the condensed pyrimidine skeleton has novel structure and excellent property, and the obtained compound can be used as an ATR inhibitor, and the in vitro kinase activity screening shows that the compound has obvious inhibiting activity on ATR.
The specific embodiment is as follows:
in the examples below, the methods of preparing some of the compounds are depicted. It will be appreciated that the following methods, as well as other methods known to those of ordinary skill in the art, may be applicable to the preparation of all compounds described herein. The examples are intended to illustrate, but not limit the scope of the invention. The nuclear magnetic resonance hydrogen spectrum of the compound is measured by Bruker ARX-600, and the mass spectrum is measured by a Waters ACQUITY triple four-stage liquid chromatography-mass spectrometer; the reagents used are analytically pure or chemically pure.
Example 1 (R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6-methanesulfonyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine
1.1 Synthesis of ethyl 2-amino-2-methylpropionate hydrochloride (1)
40g (488.9 mmol) of 2-amino-2-methylpropanoic acid was added to 400mL of absolute ethanol in an ice bath, 69.1g (580 mmol) of thionyl chloride was added dropwise to the reaction mixture, and the reaction mixture was heated to 80℃and reacted for 10 hours. After the reaction, the reaction mixture was concentrated to obtain 65g of a white solid, with a yield of 97%. Without further purification, it was used directly in the next reaction. MS (ESI) m/z 132.0[ M+H ] ] + 。
1.2 Synthesis of ethyl 3- (2, 2-dimethyl-3-ethoxy-3-oxo) -aminopropionate (2)
25g (149 mmol) of ethyl 2-amino-2-methylpropionate hydrochloride, 32.38g (178.9 mmol) of ethyl 3-bromopropionate, 96g (695.6 mmol) of DIPEA and 24g (144.5 mmol) of KI were added to acetonitrile in this order, and reacted at 80℃for 96 hours. After the reaction, the reaction solution was cooled to room temperature, suction-filtered, and the filtrate was concentrated to give 22g of brown oil in a yield of 65%, which was used directly in the next step without further purification.
1.3 Synthesis of ethyl 3- (1-benzyl-2, 2-dimethyl-3-ethoxy-3-oxo) -aminopropionate (3)
34g (147.0 mmol) of intermediate 2 is added into 20mL of DMF under ice bath, 3.6g (150 mmol) of NaH is slowly added into the reaction solution, the temperature is controlled to be 0-3 ℃, stirring is carried out for 30min, 30g (175.4 mmol) of bromobenzyl is slowly added into the reaction solution in a dropwise manner, and the reaction is carried out for 24h at room temperature after the dropwise addition. After the reaction, the reaction mixture was poured into water and extracted with EtOAc (50 mL. Times.3). The organic layer was washed with 120mL of saturated brine, dried, filtered, and the filtrate was concentrated. The residue was purified by column chromatography to give 23.6g of a colorless oil in 50% yield. MS (ESI) m/z 322.2[ M+H ] +.
1.4 Synthesis of 1-benzyl-2, 2-dimethyl-4-carboxylic acid ethyl ester-3-oxo-pyrrolidine (4)
20g (62.2 mmol) of intermediate 3 and 8.5g (126 mmol) of sodium ethoxide were added successively to 130mL of dry toluene at room temperature, and the temperature was raised to 85℃for reaction for 8h. After the reaction, the reaction solution was concentrated, and the residue was poured into water and extracted with DCM (50 ml×3). The organic layer was washed with 120mL of saturated brine, dried, filtered and concentrated in vacuo to give 10.27g of a brown oil in 60% yield, which was used in the next step without further purification. MS (ESI) m/z 276.2[ M+H ]] + 。
1.5 Synthesis of 6-benzyl-7, 7-dimethyl-6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine-2, 4 (3H) -dione ((5)
20g (72.6 mmol) of intermediate 4, 17.46g (290.7 mmol) of urea are added in succession to the flask and reacted for 8h at 180 ℃. After the reaction is finished, 50mL of water is added into the reaction liquid after the reaction liquid is slightly cooled, the filtration is carried out, and 13.2g of pale yellow solid is obtained after the filter cake is dried, and the yield is 67%. MS (ESI) m/z 269.9[ M-H ]] - 。
1.6 6-benzyl-2, 4-dichloro-7, 7-dimethyl-6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine (6)
10g (36.9 mmol) of intermediate 5 was slowly added to 150mL POCl under ice-bath 3 In the middle, reflux overnight under nitrogen atmosphere. After the reaction, the reaction mixture was cooled to room temperature and concentrated under reduced pressure, the residue was poured into ice water, the pH was adjusted to 8-9, extracted with methylene chloride (30 mL. Times.3), the organic layers were combined, washed with 30mL of saturated brine, dried, filtered off with suction, and the filtrate was concentrated, and the residue was purified by column chromatography to give 4.5g of pale yellow solid with a yield of 40%.
1.7 Synthesis of (R) -7, 7-dimethyl-2-chloro-4- (3-methylmorpholin-4-yl) -6-benzyl-5, 7-dihydro-6H-pyrrolo [3,4-d ] pyrimidine (7)
5g (16.2 mmol) of intermediate 6, 1.8g (17.8 mmol) of (R) -3-methylmorpholine and 6.29g (48.6 mmol) of DIPEA were added in succession to 10mL of DMF at room temperature and reacted for 8h at 50 ℃. After the reaction, the reaction mixture was cooled to room temperature, poured into 10mL of water, extracted with ethyl acetate (20 mL. Times.3), and the organic phase was concentrated to give a pale yellow oil, which was purified by column chromatography to give 4.2g of pale yellow solid with a yield of 70%. MS (ESI), m/z 373.1[ M+H ]] + 。
1.8 Synthesis of (R) -7, 7-dimethyl-2- (1H-indol-4-yl) -4- (3-methylmorpholin-4-yl ] -6-benzyl-5, 7-dihydro-6H-pyrrolo [3,4-d ] pyrimidine (8)
2.24g (6 mmol) of intermediate 7, 2.19g (9 mmol) of 4-indoleboronic acid pinacol ester were added to 15mL of absolute ethanol at room temperature, degassed three times, 0.21g (0.3 mmol) of ditriphenylphosphine palladium dichloride was added, degassed three times, 5mL (3.8 g,17.9 mmol) of aqueous potassium phosphate solution was added at 70℃and reacted for 16h at 75℃after the addition, the organic phase was concentrated, 10mL of water was added to the residue, extracted with dichloromethane (10 mL. Times.3), the organic phase was concentrated, and column chromatography was purified to give an off-white solid, 2.1g, yield 78%. MS (ESI), m/z 454.1[ M+H ] ] + ,452.0[M-H] - 。
1.9 Synthesis of (R) -7, 7-dimethyl-2- (1H-indol-4-yl) -4- (3-methylmorpholin-4-yl) -5, 7-dihydro-6H-pyrrolo [3,4-d ] pyrimidine (9)
1.5g (3.3 mmol) of intermediate 8 are reacted at room temperature,0.75g of palladium hydroxide/carbon is added into 20mL of absolute ethyl alcohol in sequence, the reaction is carried out for 24 hours at 60 ℃ under the hydrogen atmosphere, after the reaction is finished, the reaction liquid is filtered by diatomite, and the filtrate is concentrated to obtain 0.99g of off-white solid with the yield of 80 percent. MS (ESI), m/z 364.0[ M+H ]] + ,362.1[M-H] - 。
1.10 Synthesis of (R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6-methanesulfonyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine (Compound of example 1)
0.08g (0.2 mmol) of intermediate 9 and 0.04g (0.3 mmol) of triethylamine are sequentially added into 3mL of dry dichloromethane at room temperature, 0.042g (0.3 mmol) of methanesulfonyl chloride is slowly dripped into the reaction liquid in an ice bath, and the reaction is carried out for 2h at room temperature after the dripping. After the reaction, 5mL of water was added to the reaction mixture, which was extracted with methylene chloride (10 mL. Times.3), and the organic phase was concentrated and purified by column chromatography to give a white solid in 60% yield.
The compounds of examples 2 to 20 were synthesized using alkyl or aromatic acid chloride according to the synthesis method of example 1, the structures and melting points of examples 1 to 20, MS, 1 The H-NMR data are shown in Table 1.
Table 1 examples 1 to 20
/>
/>
/>
/>
/>
Example 21 (R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7-methylsulfonyl-4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine
21.1 Synthesis of ethyl 4-aminobutyrate hydrochloride
40g (488.9 mmol) of 4-aminobutyric acid was added to 400mL of absolute ethanol in ice bath, 80g (672.4 mmol) of thionyl chloride was slowly added dropwise, and the mixture was reacted at 80℃for 15 hours. After the reaction, the reaction mixture was concentrated to obtain 68g of a white solid, and the yield was 95%. Without further purification, it was used directly in the next reaction. MS (ESI) m/z 132.1[ M+H ]] + 。
21.2 Synthesis of ethyl 4- (2, 2-dimethyl-3-ethoxy-3-oxo) aminobutyrate
18.14g (118.1 mmol) of ethyl 4-aminobutyrate hydrochloride, 27.62g (141.6 mmol) of ethyl 2-bromo-2-methylpropionate, 65g (470.3 mmol) of potassium carbonate and 19.5g (117.5 mmol) of potassium iodide were successively added to 50mL of DMF and reacted at 100℃for 72 hours at room temperature. The reaction solution was cooled to room temperature, a large amount of white solid was precipitated, insoluble matter was removed by suction filtration, and was used directly in the next step without further purification. MS (ESI) m/z 246.1[ M+H ]] + 。
21.3 Synthesis of ethyl 4- (1-benzyl-2, 2-dimethyl-3-ethoxy-3-oxo) aminobutyrate
Under ice bath, 27.3g (125.6 mmol) of ethyl 4- (2, 2-dimethyl-3-ethoxy-3-oxo) aminobutyrate was added to 20mL of DMF, 3.6g (150 mmol) of NaH was slowly added to the reaction solution, the temperature was controlled to 0-3 ℃, stirring was carried out for 30min, 24g (140.3 mmol) of bromobenzyl was slowly added dropwise to the reaction solution, the reaction was completed at room temperature for 24h, and after the reaction was completed, the reaction solution was poured into 50mL of water and extracted with EtOAc (60 mL. Times.3). The organic layer was washed with saturated brine (2X 20 mL), dried, filtered and concentrated in vacuo. The residue was purified by column chromatography to give 23.5g of a colorless oil in 50% yield. MS (ESI) m/z 322.2[ M+H ] ] + 。
21.4 Synthesis of 1-benzyl-2, 2-dimethyl-4-carboxylic acid ethyl ester-3-oxo piperidine
20g (59.6 mmol) of ethyl 4- (1-benzyl-2, 2-dimethyl-3-ethoxy-3-oxo) aminobutyrate and 7.69g (113 mmol) of sodium ethoxide were added successively to 130mL of dry toluene at room temperature, and the mixture was heated to 85℃for reaction. After the reaction, 30mL of water was added to the reaction mixture, extracted with methylene chloride (3X 40 mL), the organic layers were combined, washed with saturated brine (2X 20 mL), dried over anhydrous sodium sulfate, suction filtered, and the filtrate was evaporated to dryness to give 11.53g of a brown oil in 74% yield, which was used directly in the next reaction without further purification.
21.5 Synthesis of 7-benzyl-8, 8-dimethyl-5, 6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine-2, 4 (1H, 3H) -dione
3.4g (147.8 mmol) of finely divided metallic sodium are added to 140mL of absolute ethanol under ice bath and stirred. After the metal sodium was completely consumed, 13.5g (224.7 mmol) of urea and 14.7g (56.2 mmol) of ethyl 1-benzyl-2, 2-dimethyl-4-carboxylate-3-oxopiperidine were added to the reaction solution, and heated under reflux for 24 hours. After the reaction, the reaction solution was cooled to room temperature. The reaction solution was concentrated under reduced pressure, the residue was poured into ice water, the pH was adjusted to 6-7 with acetic acid under ice bath, filtration was performed, the cake was washed with ice water, and the cake was the product, which was dried to give 9.6g of brown solid with a yield of 60%. MS (ESI) m/z 286.1[ M+H ] ] + 。
21.6 Synthesis of 7-benzyl-2, 4-dichloro-8, 8-dimethyl-5, 6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine
10g (35.1 mmol) of 7-benzyl-8, 8-dimethyl-5, 6,7, 8-tetrahydropyrido [3,4-d ] are placed in an ice bath]Pyrimidine-2, 4 (1H, 3H) -dione was slowly added to 200mL POCl 3 In the middle, reflux overnight under nitrogen atmosphere. After the reaction, the reaction mixture was cooled to room temperature and concentrated under reduced pressure, the residue was poured into ice water, the pH was adjusted to 8-9, dichloromethane (40 mL. Times.3) was extracted, the organic layers were combined, washed with saturated brine (20 mL. Times.3), dried over anhydrous sodium sulfate, suction-filtered, the filtrate was evaporated to dryness, and the residue was purified by column chromatography to give 7.8g of pale yellow solid with a yield of 70%. MS (ESI) m/z 322.1[ M+H ]] + 。
21.7 Synthesis of (R) -8, 8-dimethyl-2-chloro-4- (3-methylmorpholin-4-yl) -7-benzyl-5, 6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine
To 1.93g (6 mmol) of 7-benzyl-2, 4-dichloro-8, 8-dimethyl-5, 6,7, 8-tetrahydropyrido [3,4-d ] at room temperature]To a solution of pyrimidine in DMF was added 0.67g (6.6 mmol) (R) -3-methylmorpholine and 2.3g (17.8 mmol) DIPEA. The reaction mixture was stirred at 50℃for 5h. After the reaction, the reaction mixture was cooled to room temperature, the residue was poured into ice water, ethyl acetate (10 ml×3) was extracted, the organic layers were combined, washed with saturated brine (5 ml×3), dried over anhydrous sodium sulfate, suction-filtered, the filtrate was evaporated to dryness, and the residue was purified by column chromatography to give 1.58g of pale yellow solid with a yield of 68%. MS (ESI), m/z 373.1[ M+H ] ] + ; 1 H NMR(600MHz,DMSO-d 6 )δ7.39(d,J=7.1Hz,2H),7.33(t,J=7.6Hz,2H),7.24(t,J=7.3Hz,1H),4.08(q,J=6.4Hz,1H),3.80(dd,J=11.3,1.8Hz,1H),3.71(d,J=14.1Hz,1H),3.62(d,J=14.1Hz,1H),3.59–3.56(m,2H),3.55(s,1H),3.47(td,J=11.5,2.6Hz,1H),3.34(dd,J=11.2,2.6Hz,1H),2.50–2.47(m,2H),2.46–2.43(m,2H),1.43(d,J=14.3Hz,6H),1.21(d,J=6.7Hz,3H)。
21.8 Synthesis of (R) -8, 8-dimethyl-2- (1H-indol-4-yl) -4- (3-methylmorpholin-4-yl) -7-benzyl-5, 6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine
1.7g (4.3 mmol) of (R) -8, 8-dimethyl-2-chloro-4- (3-methylmorpholin-4-yl) -7-benzyl-5, 6,7, 8-tetrahydropyrido [3,4-d ] are reacted successively at room temperature]Pyrimidine, 1.6g (6.5 mmol) 4-indoleboronic acid pinacol ester were added to 15mL absolute ethanol, degassed three times, 0.15g (0.2 mmol) bis triphenylphosphine palladium dichloride was added, degassed three times, 5mL (2.8 g,13.2 mmol) aqueous potassium phosphate was added at 70℃and reacted at 75℃for 16h, the reaction was completed, the organic phase was concentrated, 5mL water was added to the residue, extracted with dichloromethane (20 mL. Times.3), the organic phase was concentrated, and column chromatography was performed to give 1.4g of an off-white solid with a yield of 79%. M.p, 124.6-128.7 ℃; 1 H NMR(600MHz,DMSO-d 6 )δ11.24(s,1H),8.14(d,J=7.4Hz,1H),7.52(d,J=7.9Hz,1H),7.45(dd,J=10.8,5.5Hz,4H),7.35(t,J=7.5Hz,2H),7.26(t,J=7.3Hz,1H),7.20(t,J=7.7Hz,1H),4.05(d,J=6.3Hz,1H),3.86(dd,J=12.3,7.3Hz,2H),3.71(dd,J=10.9,2.0Hz,1H),3.63(dd,J=13.3,8.1Hz,2H),3.58(d,J=11.7Hz,1H),3.52(d,J=13.3Hz,1H),3.46(dd,J=17.4,6.6Hz,1H),2.61–2.53(m,4H),1.64(s,3H),1.58(s,3H),1.23(d,J=6.5Hz,3H)。
21.9 (R) -8, 8-dimethyl-2- (1H-indol-4-yl) -4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ]]Synthesis of pyrimidine 1.5g (3.2 mmol) of (R) -8, 8-dimethyl-2- (1H-indol-4-yl) -4- (3-methylmorpholin-4-yl) -7-benzyl-5, 6,7, 8-tetrahydropyrido [3,4-d ] are taken at room temperature]Pyrimidine and 0.15g palladium hydroxide/carbon are added into 20mL absolute ethyl alcohol in sequence, the reaction is carried out for 24 hours at 60 ℃ under the hydrogen atmosphere, after the reaction is finished, the reaction liquid is filtered through diatomite, and the filtrate is concentrated to obtain 0.84g of off-white solid with the yield of 70 percent. M.p, 99.7-102.9 ℃; MS (ESI), m/z 378.3[ M+H ] ] + ; 1 H NMR(600MHz,DMSO-d 6 )δ11.25(s,1H),8.15–8.06(m,1H),7.51(dd,J=7.3,4.6Hz,1H),7.45(d,J=1.9Hz,1H),7.41(s,1H),7.24–7.14(m,1H),4.03(d,J=2.1Hz,1H),3.89(d,J=10.5Hz,1H),3.75(d,J=10.9Hz,1H),3.62(d,J=11.1Hz,2H),3.46(d,J=2.1Hz,1H),3.01–2.91(m,2H),2.76(s,2H),2.65(d,J=3.0Hz,2H),1.52(dd,J=15.4,3.7Hz,6H),1.23(d,J=5.6Hz,3H)。
21.10 Synthesis of (R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7-methylsulfonyl-4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine (example 21)
0.08g (0.2 mmol) of (R) -8, 8-dimethyl-2- (1H-indol-4-yl) -4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine and 0.04g (0.3 mmol) of triethylamine are added to 3mL of dry dichloromethane in sequence at room temperature, 0.042g (0.3 mmol) of methanesulfonyl chloride is slowly dripped into the reaction liquid under ice bath, and the reaction is carried out for 2H at room temperature. After the reaction, 5mL of water was added to the reaction mixture, which was extracted with methylene chloride (20 mL. Times.3), and the organic phase was concentrated, and purified by column chromatography to give 0.05g of a white solid in 60% yield.
The compounds of examples 22 to 43 were synthesized according to the synthesis method of example 21 using alkyl or aromatic acid chlorides, the structures, chemical names and melting points of examples 21 to 43, MS, 1 The H-NMR data are shown in Table 2.
Table 2 examples 21 to 43
/>
/>
/>
/>
/>
Example 44 (R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7- (2-dimethylaminoacetyl) -4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine
44.1 Synthesis of (R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7- (2-chloroacetyl) -4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine
0.2g (0.5 mmol) of (R) -8, 8-dimethyl-2- (1H-indol-4-yl) -4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine and 0.11g (1.1 mmol) of triethylamine are added to 3mL of dry dichloromethane in sequence at room temperature, 0.120g (1.1 mmol) of chloroacetyl chloride is slowly dripped into the reaction liquid under ice bath, and the dripping is completed, and the reaction is carried out at room temperature for 2H. After the reaction, 5mL of water was added to the reaction mixture, the mixture was extracted with methylene chloride (10 mL. Times.3), and the organic phase was concentrated, and purified by column chromatography to give 0.19g of a gray solid in 66% yield.
44.2 Synthesis of (R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7- (2-dimethylaminoacetyl) -4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine (example 44)
0.1g (0.22 mmol) of (R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7- (2-chloroacetyl) -4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine, 0.026g (0.32 mmol) of dimethylamine hydrochloride, 0.12g (0.86 mmol) of potassium carbonate were added to 3mL of acetonitrile at room temperature and reacted at 60℃for 5 hours. After the reaction, the reaction mixture was cooled to room temperature, the reaction mixture was concentrated, 5mL of water was added to the reaction mixture, the mixture was extracted with methylene chloride (10 mL. Times.3), and the organic phase was concentrated and purified by column chromatography to give 0.079g of a white solid in 79% yield.
44.3 Synthesis of (R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7- [2- (4-methylpiperazin-1-yl) acetyl ] -4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine (example 45)
N-methylpiperazine is used as a raw material, and (R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7- [2- (4-methylpiperazin-1-yl) acetyl ] -4- (3-methylmorpholine-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine is synthesized according to a synthesis method of 44.2. The yield thereof was found to be 77%.
Examples 44 to 45 were structured, chemical name, melting point, MS, 1 The H-NMR data are shown in Table 3.
TABLE 3 examples 44 to 45
Synthesis of (R) -7, 7-dimethyl-2- (1H-7-azaindol-4-yl) -4- (3-methylmorpholin-4-yl) using 7-aza-4-indoleboronic acid ester as starting material according to the Synthesis method of 1.1.8 in example 1]-6-benzyl-5, 7-dihydro-6H-pyrrolo [3,4-d]Pyrimidine or (R) -8, 8-dimethyl-2- (1H-7-azaindol-4-yl) -4- (3-methylmorpholin-4-yl) -7-benzyl-5, 6,7, 8-tetrahydropyrido [3,4-d ]]Pyrimidine. (R) -7, 7-dimethyl-2- (1H-7-azaindol-4-yl) -4- (3-methylmorpholin-4-yl) -5, 7-dihydro-6H-pyrrolo [3,4-d ] was then synthesized according to the method of synthesis 1.1.9 in example 1]Pyrimidine or (R) -8, 8-dimethyl-2- (1H-7-azaindol-4-yl) -4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] ]Pyrimidine was synthesized by the method of 1.10 in example 1 using alkyl or aromatic acid chloride to give the compounds of examples 46 to 57, in factExamples 46 to 57 were structured, chemical name, melting point, MS, 1 The H-NMR data are shown in Table 4.
Table 4 examples 46 to 57
/>
/>
/>
Example 58 (R) -7, 7-dimethyl-2- (1H-indol-2-one-4-yl) -6-acetyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine
58.1 Synthesis of (R) -7, 7-dimethyl-2-chloro-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine
1g (2.7 mmol) of (R) -7, 7-dimethyl-2-chloro-4- (3-methylmorpholin-4-yl) -6-benzyl-5, 7-dihydro-6H-pyrrolo [3,4-d ] are taken up at room temperature]Pyrimidine was added to 10mL of methylene chloride, 1.5g (10.5 mmol) of 1-chloroethyl chloroformate was added dropwise under ice bath, and after completion of the dropwise addition, the mixture was reacted at room temperature for 10 hours, the solvent was evaporated, 10mL of methanol was added to the residue, and the reaction was refluxed for 3 hours. After the reaction, the solvent was evaporated to dryness, the residue was pH-adjusted to 7-8 with 1N NaOH solution, extracted with methylene chloride (10 mL. Times.3), dried, filtered off with suction, and the filtrate was concentrated to give 0.3g of a pale yellow oil in 40% yield. . MS (ESI) m/z 283.12[ M+H ]] + 。
58.2 Synthesis of (R) -7, 7-dimethyl-2-chloro-6-acetyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine
(R) -7, 7-dimethyl-2-chloro-6-acetyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine was synthesized in the same manner as the synthesis method of 1.10 in example 1, starting from propionyl chloride and (R) -7, 7-dimethyl-2-chloro-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine.
58.3 Synthesis of (R) -7, 7-dimethyl-2- (1H-indol-2-one-4-yl) -6-benzoyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine
With (R) -7, 7-dimethyl-2-chloro-6-acetyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d]Pyrimidine and 4-boronic acid ester-indol-2-one starting materials were synthesized (R) -7, 7-dimethyl-2- (1H-indol-2-one-4-yl) -6-benzoyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] according to the synthesis method of 1.8 in example 1]Pyrimidine. The yield thereof was found to be 56%. MS (ESI) m/z 437.0[ M+H ]] + 。
The compounds of examples 59 to 65 were synthesized using (R) -7, 7-dimethyl-2-chloro-6-acetyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine and the different substituted borates as starting materials, using 58.3 synthesis methods, and using (R) -7, 7-dimethyl-2-chloro-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine and m-methylsulfonyl benzoyl chloride or p-sulfonylbenzoyl chloride as starting materials to give the corresponding intermediates according to 57.2 synthesis methods, followed by reaction with the different substituted borates or the different substituted amines as starting materials. The structure, chemical name and MS data of examples 58-75 are shown in table 5.
Table 5 examples 58 to 75
/>
/>
/>
/>
The compounds of examples 76 to 80 were synthesized by the synthesis method of example 1 using various substituted small molecular amines and intermediate 6 as raw materials, the structures, chemical names and melting points of examples 76 to 80, MS, 1 The H-NMR data are shown in Table 6.
TABLE 6 examples 76 to 80
/>
The ATR enzyme activity of the compound of the present invention was studied, and the results were as follows
The fused pyrimidine compounds of the formula I are prepared by performing in vitro ATR enzyme activity test on the fused pyrimidine compounds of the formula I according to the invention by using a fluorescence assay method, wherein the following compounds are prepared by the above examples.
The kinase buffer consists of 50mM HEPES (pH 7.5), 0.0015% Brij-35, 1M MnCl 2 Composition is prepared. Stop buffer consisted of 100mM HEPES (pH 7.5), 0.015% Brij-35, 0.2%Coating Reagent#3, 50mM EDTA. The compound was diluted with 100% dimethyl sulfoxide to 1000/3 times the final desired maximum inhibitor concentration. To two wells, 100 μl of dimethyl sulfoxide was added, and the compound-free control and enzyme-free control were performed in the same 96-well plate. This plate is denoted as source plate. Transfer 40 μl of compound from the source plate to a new 384 well plate as an intermediate plate, transfer 60nL of compound to the assay plate by Echo in 100% dimethyl sulfoxide. 2 parts of an enzyme solution was prepared, and kinase was added to the kinase base buffer. Transfer 2 times enzyme solution to assay plate, 3 To each well of the 84-well assay plate, 10. Mu.L of enzyme solution was added. Incubate at room temperature for 10min. FAM-labeled peptide and ATP were added to kinase base buffer, peptide solution was transferred to assay plates, and 10 μl of peptide solution was added to each well of 384-well assay plates. The kinase reaction was stopped, the transformation data was copied from the Caliper program, and drug IC was obtained by the Bliss method 50 Values. ATR enzyme IC of some examples 50 The activity data are shown in Table 7.
TABLE 7 ATR enzyme IC of the examples section 50 Activity data
Examples | IC 50 (nM) |
Example 3 | 7.6 |
Example 4 | 8.2 |
Example 7 | 7.2 |
Example 9 | 4.0 |
Example 10 | 3.0 |
Example 11 | 7.0 |
Example 13 | 4.7 |
Example 14 | 4.2 |
Example 15 | 3.8 |
Example 16 | 3.0 |
Example 17 | 5.0 |
Example 19 | 5.8 |
Example 20 | 4.3 |
Example 24 | 8.0 |
Example 25 | 8.7 |
Example 28 | 8.9 |
Example 29 | 9.4 |
Example 31 | 6.1 |
Example 40 | 4.7 |
Example 41 | 9.4 |
Example 43 | 9.1 |
Example 48 | 6.6 |
AZ20 | 4.8 |
From the above table, it is described that the compounds of the general formula have good ATR inhibitory activity, and that some of the compounds are equivalent or superior to the positive control AZ20.
Further experiments were then performed to inhibit the activity of LOVO cells and HT-29 cells in vitro on the partially fused pyrimidine derivatives of formula I above according to the invention.
Human colon cancer HT-29 and LOVO cells were purchased from the Shanghai cell Bank (CAS) of the national academy of sciences. Cells were recovered and passaged 2-3 times for stabilization, and cells in the logarithmic growth phase were collected, prepared into single cell suspensions and counted, and the cell concentration was adjusted to the desired concentration, and 100 μl per well was added to a 96-well cell culture plate. 100. Mu.L of complete medium of test compound or positive control compound or complete medium of control (2 wells per concentration) was added per well and incubated in an incubator for 72 h. The fluorescence intensity (530/590 nm) of each well was measured using the Alamar blue method, and proliferation rates at each concentration were calculated.
Proliferation rate = 1- [ (negative control well-test well)/(negative control well-positive control well) ×100% ]
The results of the experiments on LOVO cells L and HT-29 for some of the compounds are shown in Table 8.
Table 8 cell proliferation Rate (%)
Cell activity test results of the compounds show that the activity of part of the compounds on LOVO and HT-29 cells is equivalent to or better than that of the positive control AZ20.
Meanwhile, in vitro kinase and cell activity test results show that the compound has good ATR enzyme activity and excellent cell activity, and part of the compound activity is better than that of a positive control medicine AZ20.
Claims (11)
1. A fused pyrimidine derivative, characterized in that: the derivative is a compound shown in a general formula I and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a prodrug thereof,
wherein,
R 1 and R is 2 Together with the nitrogen atom to which they are attached form a 4-10 membered heterocyclic group containing at least 1-4 heteroatoms, said heterocyclic group optionally being substituted with 1-3R's, which may be the same or different 3 Optionally substituted with 1-2 oxo groups;
R 3 is H, cyano, halogen, (C) 1 -C 6 ) Alkyl, halo (C) 1 -C 6 ) Alkyl, (C) 1 -C 6 ) Alkoxy, halo (C) 1 -C 6 ) Alkoxy, carboxyl, (C) 1 -C 6 ) Alkoxycarbonyl, unsubstituted or substituted by 1 to 2 (C) 1 -C 6 ) An alkyl-substituted carbamoyl group;
a is unsubstituted or substituted by 1 to 3 identical or different R 4 Substituted 4-10 membered heterocyclyl, (C) 6 -C 10 ) Aryl, 5-10 membered heteroaryl;
n is 1, 2 or 3;
y is-C (O) -, -S (O) 2 -、-S(O)-、-C(S)-、-CH 2 -、-C(O)CH 2 -、-CH 2 C(O)-;
L is unsubstituted or substituted by 1 to 3 identical or different R 7 Substituted (C) 1 -C 6 ) Alkyl, (C) 1 -C 6 ) Alkoxy, (C) 2 -C 6 ) Alkenyl group (C) 3 -C 6 ) Cycloalkyl, (C) 6 -C 10 ) Aryl, 5-10 membered heteroaryl, -NR 5 R 6 ;
R 5 、R 6 The same or different are each independently selected from hydrogen, (C) 1 -C 6 ) Alkyl, (C) 3 -C 6 ) Cycloalkyl, 4-10 membered heterocyclyl, (C) 6 -C 10 ) Aryl, 5-10 membered heteroaryl;
or R is 5 And R is 6 Together with the nitrogen atom to which they are attached, form a 4-10 membered heterocyclic group containing at least 1-4 heteroatoms, said heterocyclic group optionally being substituted with 1-2 oxo groups;
R 4 ,R 7 is halogen, hydroxy, nitro, cyano, carboxyl, (C) 1 -C 6 ) Alkyl, (C) 1 -C 6 ) Alkoxy, halo (C) 1 -C 6 ) Alkyl, halo (C) 1 -C 6 ) Alkoxy, (C) 1 -C 6 ) Alkyl acyl group (C) 1 -C 6 ) Alkoxycarbonyl, (C) 1 -C 6 ) Alkylamido group (C) 1 -C 6 ) Alkylsulfinyl, (C) 1 -C 6 ) Alkylsulfonyl, (C) 1 -C 3 ) Alkylene dioxy, unsubstituted or substituted by 1 to 2 (C) 1 -C 6 ) Amino substituted by alkyl, unsubstituted or substituted by 1-2 (C 1 -C 6 ) An alkyl-substituted carbamoyl group;
the aryl is phenyl or naphthyl; heteroaryl is a monocyclic or polycyclic, unsaturated cyclic system containing one or more heteroatoms; heterocyclyl is a monocyclic, multicyclic, bridged or spiro ring system containing one or more heteroatoms.
2. A fused pyrimidine derivative as claimed in claim 1, wherein: the derivative is a compound of a general formula I and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a prodrug thereof,
wherein,
R 1 and R is 2 Together with the nitrogen atom to which they are attached form a 4-10 membered heterocyclic group containing at least 1-3 heteroatoms, said heterocyclic group optionally being substituted with 1-2R's, which may be the same or different 3 Substituted or substituted with 1-2 oxo groups;
R 3 is H, cyano, halogen, (C) 1 -C 4 ) Alkyl, (C) 1 -C 4 ) Alkoxy, halo (C) 1 -C 4 ) Alkyl, halo (C) 1 -C 4 ) Alkoxy, carboxyl, (C) 1 -C 4 ) Alkoxycarbonyl, unsubstituted or substituted by 1 to 2 (C) 1 -C 4 ) Amino substituted by alkyl, unsubstituted or substituted by 1-2 (C 1 -C 4 ) An alkyl-substituted carbamoyl group;
a is unsubstituted or substituted by 1-2 identical or different R 4 Substituted 4-10 membered heterocyclyl, (C) 6 -C 10 ) Aryl, 5-10 membered heteroaryl;
n is 1 or 2;
y is-C (O) -, -S (O) 2 -、-C(O)CH 2 -、-CH 2 C(O)-;
L is unsubstituted or substituted by 1 to 3 identical or different R 7 Substituted (C) 1 -C 4 ) Alkyl, (C) 1 -C 4 ) Alkoxy, (C) 2 -C 4 ) Alkenyl group (C) 3 -C 6 ) Cycloalkyl, (C) 6 -C 10 ) Aryl, 5-10 membered heteroaryl, -NR 5 R 6 ;
R 5 、R 6 The same or different are each independently selected from hydrogen, (C) 1 -C 4 ) Alkyl, (C) 3 -C 4 ) Cycloalkyl, 4-10 membered heterocyclyl, (C) 6 -C 10 ) Aryl, 5-6 membered heteroaryl;
Or R is 5 And R is 6 Together with the nitrogen atom to which they are attached, form a 4-10 membered heterocyclic group containing at least 1-4 heteroatoms, said heterocyclic group optionally being substituted with 1-2 oxo groups;
R 4 ,R 7 is halogen, hydroxy or nitroCyano, carboxyl, (C) 1 -C 4 ) Alkyl, (C) 1 -C 4 ) Alkoxy, halo (C) 1 -C 4 ) Alkyl, halo (C) 1 -C 4 ) Alkoxy, (C) 1 -C 4 ) Alkyl acyl group (C) 1 -C 4 ) Alkoxycarbonyl, (C) 1 -C 4 ) Alkylamido group (C) 1 -C 4 ) Alkylsulfinyl, (C) 1 -C 4 ) Alkylsulfonyl, (C) 1 -C 3 ) Alkylene dioxy, unsubstituted or substituted by 1 to 2 (C) 1 -C 4 ) Amino substituted by alkyl, unsubstituted or substituted by 1-2 (C 1 -C 4 ) An alkyl-substituted carbamoyl group.
3. A fused pyrimidine derivative as claimed in claim 2, wherein: the derivative is a compound shown in a general formula I and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a prodrug thereof,
wherein,
R 1 and R is 2 Together with the nitrogen atom to which they are attached form a 4-10 membered heterocyclic group containing at least 1-2 heteroatoms, said heterocyclic group optionally being substituted with 1-2R's, which may be the same or different 3 Substituted or substituted with 1-2 oxo groups;
l is unsubstituted or substituted by 1 to 3 identical or different R 7 Substituted (C) 1 -C 4 ) Alkyl, (C) 3 -C 6 ) Cycloalkyl, phenyl, 5-10 membered heteroaryl, -NR 5 R 6 。
4. A fused pyrimidine derivative as claimed in claim 3, wherein: the derivative is a compound shown in a general formula I and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a prodrug thereof,
Wherein,
l is unsubstituted or substituted by 1 to 3 identical or different R 7 Substituted (C) 1 -C 4 ) Alkyl, (C) 3 -C 6 ) Cycloalkyl, phenyl, 5-10 membered heteroaryl.
5. The fused pyrimidine derivative as claimed in claim 4, wherein: the derivative is a compound shown in a general formula I and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a prodrug thereof,
wherein,
y is-C (O) -;
R 1 and R is 2 Together with the nitrogen atom to which they are attached, form the structure:
6. the fused pyrimidine derivative as claimed in claim 5, wherein: the derivative is a compound shown in a general formula I and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a prodrug thereof,
wherein,
a is Or A as described above is optionally substituted with 1 to 3R's, which may be the same or different 4 And (3) substitution.
7. The novel fused pyrimidine derivatives as claimed in claim 6, wherein: the derivative is a compound shown in a general formula I, and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a prodrug thereof,
R 1 and R is 2 Together with the nitrogen atom to which they are attached
L is unsubstituted or substituted by 1 to 3 identical or different R 7 Substituted (C) 1 -C 4 ) Alkyl, (C) 3 -C 6 ) Cycloalkyl, phenyl, thienyl, pyrrolyl, pyrazolyl, furyl, thiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, quinolinyl, isoquinolinyl, indolyl, benzothiazolyl, benzoxazolyl;
A is And A is optionally substituted with 1 to 3R's, which may be the same or different 4 And (3) substitution.
8. The novel fused pyrimidine derivatives as claimed in claim 7, wherein: the derivative is a compound of a general formula I and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a prodrug thereof,
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6-methanesulfonyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6-acetyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6-isopropyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6-cyclopropylcarbonyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6-propionyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6-methanesulfonyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6-cyclobutylformyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (3-methoxybenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (4-methoxybenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (3, 4-dimethoxybenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (1, 3-benzodioxol-5-yl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (2, 3-dihydrobenzo [ b ] [1,4] dioxin-6-carbonyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (4-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (3-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (4-difluoromethoxybenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (4-acetylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-4-yl) -6- (3-acetylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7-methylsulfonyl 4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine;
(R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7-isopropylformyl-4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine;
(R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7-propionyl-4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine;
(R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7-benzoyl-4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine;
(R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7- (2-acryloyl) -4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine;
(R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7- (3-fluorobenzoyl) -4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine;
(R) -8, 8-dimethyl-2- (1H-indol-4-yl) -7- (3, 4-dimethoxybenzoyl) -4- (3-methylmorpholin-4-yl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-7-azaindol-4-yl) -6-methanesulfonyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-7-azaindol-4-yl) -6-cyclopropylcarbonyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-7-azaindol-4-yl) -6-benzoyl-4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-7-azaindol-4-yl) -6- (3-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (7-methyl-1H-indol-4-yl) -6- (3-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (7-methyl-1H-indol-4-yl) -6- (4-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (3 a,7 a-dihydro-1H-benzo [ d ] imidazol-1-yl) -6- (3-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (3 a,7 a-dihydro-1H-benzo [ d ] imidazol-1-yl) -6- (4-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indazol-4-yl) -6- (4-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine;
(R) -7, 7-dimethyl-2- (1H-indol-3-yl) -6- (4-methylsulfonylbenzoyl) -4- (3-methylmorpholin-4-yl) -6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine.
9. A pharmaceutical composition comprising a compound of formula I according to any one of claims 1 to 8, and stereoisomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, in admixture with a pharmaceutically acceptable carrier.
10. Use according to claim 1 or 9, characterized in that: the application of the compound of the general formula I and stereoisomers, pharmaceutically acceptable salts, solvates or prodrugs thereof or the composition containing the compound of the general formula I and stereoisomers, pharmaceutically acceptable salts, solvates or prodrugs thereof in preparing medicines for treating and/or preventing ATR-mediated diseases.
11. The use according to claim 10, wherein: the prevention of ATR mediated disease is osteosarcoma, glioblastoma, lung cancer, head and neck cancer, pancreatic cancer, gastric cancer, and brain cancer, non-small cell lung cancer, pancreatic cancer, biliary tract cancer, bladder cancer, colorectal cancer, breast cancer, ovarian cancer, multiple myeloma, skin cancer, melanoma, leukemia, or renal cancer.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210578200.XA CN117164590A (en) | 2022-05-25 | 2022-05-25 | Fused pyrimidine derivative and application thereof |
PCT/CN2023/106083 WO2023227139A1 (en) | 2022-05-25 | 2023-07-06 | Fused pyrimidine derivative and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210578200.XA CN117164590A (en) | 2022-05-25 | 2022-05-25 | Fused pyrimidine derivative and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117164590A true CN117164590A (en) | 2023-12-05 |
Family
ID=88918528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210578200.XA Pending CN117164590A (en) | 2022-05-25 | 2022-05-25 | Fused pyrimidine derivative and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117164590A (en) |
WO (1) | WO2023227139A1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2046799B1 (en) * | 2006-04-26 | 2017-07-19 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
CN111057065B (en) * | 2019-12-24 | 2021-04-23 | 沈阳药科大学 | Preparation method and application of thienopyrimidine compound |
CN115466258A (en) * | 2021-06-11 | 2022-12-13 | 成都苑东生物制药股份有限公司 | ATR inhibitors and uses thereof |
-
2022
- 2022-05-25 CN CN202210578200.XA patent/CN117164590A/en active Pending
-
2023
- 2023-07-06 WO PCT/CN2023/106083 patent/WO2023227139A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023227139A1 (en) | 2023-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6141568B1 (en) | Novel pyrazolo [3,4-d] pyrimidine compound or salt thereof | |
CN107556295B (en) | Quinazoline derivatives and process for their preparation | |
KR101828187B1 (en) | Novel fused pyrimidine compound or salt thereof | |
EP3173412B1 (en) | 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | |
JP6704422B2 (en) | Quinazoline derivative salt and method for producing the same | |
US10561646B2 (en) | EGFR inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof | |
JP6986032B2 (en) | Crystals of pyrrolopyrimidine compounds as JAK inhibitors | |
CA3104377C (en) | Heterocyclic compounds as trk inhibitors | |
JP2002544194A (en) | Quinoline derivatives as inhibitors of MEK enzyme | |
CN113717156B (en) | EGFR inhibitor, preparation method and application thereof | |
US9440981B2 (en) | Pyrrolo[2, 1-F] [1,2,4]triazine derivative and use thereof for treating tumors | |
CN112300153B (en) | Heterocyclic compound, pharmaceutical composition and application | |
EP3470415A1 (en) | 5-membered heterocycle fused with [3,4-d]pyridazinone, and manufacturing method, pharmaceutical composition, and application thereof | |
WO2018237134A1 (en) | Atropisomerism for enhanced kinase inhibitor selectivity | |
KR20190021345A (en) | Crystals of aniline pyrimidine compounds provided as EGFR inhibitors | |
EP3670500A1 (en) | Chemical compound, pharmaceutical composition thereof, and use and application thereof | |
CN111499613B (en) | N-carboxamide derivatives, method for the production thereof and their use in medicine | |
CN114380806B (en) | 2-amino-4-indolyl pyrimidine compound and preparation method and application thereof | |
EP0551527B1 (en) | Pyrroloazepine derivative | |
CN117164590A (en) | Fused pyrimidine derivative and application thereof | |
CN115490671A (en) | PARP7 inhibitors and process for preparing the same | |
WO2011078226A1 (en) | Tricyclic compound | |
CN111410667A (en) | Novel (1,2,4) triazolo (1,5-a) pyridylphosphine oxides and use thereof | |
CN115947728B (en) | Sulfonyl-containing dihydropteridinone derivatives and their use | |
WO2023046114A1 (en) | Pteridinone derivative and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40095801 Country of ref document: HK |